Preclinical studies for Ligand's G-CSFR agonist presented at ASH


A poster presentation at ASH shows Ligand Pharmaceuticals' (LGND) G-CSF receptor agonist LGD-455 "significantly increases peripheral blood neutrophils, inhibits tumor cell growth and increases apoptosis."

The company evaluated the treatment's ability to stimulate white blood cell counts in cynomolgus monkeys. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs